May 12, 2020 / 5:31 AM / a month ago

BRIEF-Innate Pharma End-Q1 Cash, Cash Equivalents And Financial Assets Of Company Amounts To 206.9 Million Euros

May 12 (Reuters) - Innate Pharma SA:

* INNATE PHARMA FIRST QUARTER 2020 REPORT

* END-Q1 CASH, CASH EQUIVALENTS AND FINANCIAL ASSETS OF COMPANY AMOUNTED TO EUR 206.9 MILLION

* FIRST PATIENT DOSED IN AVDORALIMAB (ANTI-C5AR) PHASE II CLINICAL TRIAL IN COVID-19 PATIENTS WITH SEVERE PNEUMONIA

* COVID-19 PANDEMIC COULD IMPAIR OUR ABILITY TO ACHIEVE OUR PRODUCT DEVELOPMENT OR COMMERCIALIZATION OBJECTIVES IN TIMEFRAMES WE HAD EXPECTED

* THERE IS VARYING IMPACT TO OUR PIPELINE ASSETS IN RELATION TO COVID-19

* REVENUES FOR FIRST THREE-MONTHS OF 2020 AMOUNTED TO EUR 19.3 MILLION (EUR 13.9 MILLION FOR SAME PERIOD IN 2019)

* DUE TO COVID-19, RATE OF NEW LUMOXITI PATIENTS HAS SLOWED WHICH IS EXPECTED TO IMPACT 2020 SALES Source text for Eikon: Further company coverage: (Gdansk Newsroom)

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below